Hidradenitis Suppurativa clinical trials

The registry lists 285 studies for Hidradenitis Suppurativa across more than 10 countries. 88 are recruiting or about to start. 247 of them are mainly about Hidradenitis Suppurativa (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Hidradenitis Suppurativa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 127
Recruiting: 61
Active, not recruiting: 25
Not yet recruiting: 23
Terminated: 21
Status unknown: 13

Phase

Phase 2: 91
Phase 3: 33
Phase 1: 24
Phase 4: 11
Early Phase 1: 10

Where

United States: 161
Canada: 66
Germany: 65
France: 53
Spain: 50
Poland: 45

Who runs them

Novartis Pharmaceuticals (21) · AbbVie (15) · Incyte Corporation (12) · Henry Ford Health System (7) · University of Miami (6) · UCB Biopharma SRL (6) · Montefiore Medical Center (5) · MoonLake Immunotherapeutics AG (5)

What is being tested here

Drugs under test in Hidradenitis Suppurativa studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Povorcitinib	2	4	8
Secukinumab	2	3	6
Remibrutinib	2	3	5
Roflumilast	2	0	3
Bimekizumab	1	4	6
Ruxolitinib	1	2	5
Sonelokimab	1	4	5
Lutikizumab	1	1	3
Brivekimig	1	0	2
Botulinum toxin type A	1	0	2

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · JAK inhibitors 3 open

Coming up

13phase 3 studies under way

40studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · AbbVie
Dec 2026A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · UCB Biopharma SRL
Dec 2026A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · Incyte Corporation
Feb 2027Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · Institut Pasteur
May 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) · Phase 3 · Novartis Pharmaceuticals
Jun 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · Novartis Pharmaceuticals
Aug 2027A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa · Phase 3 · Bluefin Biomedicine, Inc.
Nov 2026Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa · Sonoma Biotherapeutics, Inc.
Nov 2026Acceptability of MBSR for People With HS · University of California, San Francisco
Nov 2026Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS · Peking Union Medical College

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger. 13 (21%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 12 (20%) take healthy volunteers.

Recruiting studies that take each age, of 61
Age	Women	Men
10	7 (11%)	7 (11%)
18	60 (98%)	59 (97%)
30	60 (98%)	59 (97%)
40	60 (98%)	59 (97%)
50	59 (97%)	58 (95%)
65	57 (93%)	56 (92%)
75	51 (84%)	50 (82%)
85	41 (67%)	40 (66%)

Across all 285 studies, recruiting or not: 26% stop at 75 or younger and 13% at 65; 18% take children; 2% are for women only and 0% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hidradenitis Suppurativa studies take

Of 54 phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	17 mo11–29 · 20 studies	—	—
Phase 2	15 mo11–24 · 54 studies	15 mo10–20 · 44 studies	—
Phase 3	25 mo20–38 · 26 studies	—	—
Interventional, no phase	17 mo11–31 · 25 studies	—	—
Observational	34 mo25–… · 44 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 285. Browse all 285 → or search them.